Tumor-associated peptide antigen presented on MHC class I molecule

Tumor-associated peptide antigens presented on MHC class I molecules are short intracellular peptides (typically 8–11 amino acids) derived from mutated or aberrant proteins in cancer cells. These peptides are loaded onto MHC class I molecules in the endoplasmic reticulum via the antigen processing machinery, then transported to the cell surface, where they are displayed to cytotoxic T lymphocytes (CD8+ T cells)[1][2][3][5][9]. Recognition of these peptide-MHC complexes by T cells enables the immune system to detect and eliminate malignant cells. However, many tumors evade immune attack by downregulating components of this pathway[5][9]. These antigens are central to cancer immunotherapy approaches such as vaccination and immune checkpoint blockade, making tumor-associated peptide antigens presented on MHC class I molecules a critical and actionable immune therapeutic target[3][5][9].

Other names

MHC class I tumor-associated antigenTumor antigen (MHC-I restricted)Tumor neoantigen (presented by MHC-I)Peptide-MHC class I complex

Restoration or enhancement of antigen presentation (e.g., by upregulating MHC-I or antigen processing machinery); Boosting CD8+ T cell responses against tumor peptide antigens; Blocking immune checkpoints to unleash T cell recognition of tumor peptide-MHC complexes